United Kingdom - English - myHealthbox

caduceus pharma ltd. - pemetrexed - concentrate for solution for infusion - 25mg - folic acid analogues - malignant pleural mesothelioma pemetrexed in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancer pemetrexed in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology pemetrexed is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy

United Kingdom - English - myHealthbox

caduceus pharma ltd - simvastatin - film-coated tablets - 10mg - hmg-coa reductase inhibitors - hypercholesterolaemia treatment of primary hypercholesterolaemia or mixed dyslipidaemia, as an adjunct to diet, when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate treatment of homozygous familial hypercholesterolaemia as an adjunct to diet and other lipid-lowering treatments (e.g. ldl apheresis) or if such treatments are not appropriate. cardiovascular prevention reduction of cardiovascular mortality and morbidity in patients with manifest atherosclerotic cardiovascular disease or diabetes mellitus, with either normal or increased cholesterol levels, as an adjunct to correction of other risk factors and other cardioprotective therapy

United Kingdom - English - myHealthbox

caduceus pharma ltd - simvastatin - film-coated tablets - 20mg - hmg-coa reductase inhibitors - hypercholesterolaemia treatment of primary hypercholesterolaemia or mixed dyslipidaemia, as an adjunct to diet, when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate treatment of homozygous familial hypercholesterolaemia as an adjunct to diet and other lipid-lowering treatments (e.g. ldl apheresis) or if such treatments are not appropriate. cardiovascular prevention reduction of cardiovascular mortality and morbidity in patients with manifest atherosclerotic cardiovascular disease or diabetes mellitus, with either normal or increased cholesterol levels, as an adjunct to correction of other risk factors and other cardioprotective therapy

United Kingdom - English - myHealthbox

caduceus pharma ltd - simvastatin - film-coated tablets - 40mg - hmg-coa reductase inhibitors - hypercholesterolaemia treatment of primary hypercholesterolaemia or mixed dyslipidaemia, as an adjunct to diet, when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate treatment of homozygous familial hypercholesterolaemia as an adjunct to diet and other lipid-lowering treatments (e.g. ldl apheresis) or if such treatments are not appropriate. cardiovascular prevention reduction of cardiovascular mortality and morbidity in patients with manifest atherosclerotic cardiovascular disease or diabetes mellitus, with either normal or increased cholesterol levels, as an adjunct to correction of other risk factors and other cardioprotective therapy

United Kingdom - English - myHealthbox

caduceus pharma ltd - atorvastatin - film-coated tablets - 10mg - lipid modifying agents, hmg-coa-reductase inhibitors - it is indicated as an adjunct to diet for reduction of elevated total cholesterol (total-c), ldl-cholesterol (ldl-c), apolipoprotein b, and triglycerides in adults adolescents and children aged 10 years or older or older with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate.

United Kingdom - English - myHealthbox

caduceus pharma ltd - atorvastatin - film-coated tablets - 20mg - lipid modifying agents, hmg-coa-reductase inhibitors, - it is indicated as an adjunct to diet for reduction of elevated total cholesterol (total-c), ldl-cholesterol (ldl-c), apolipoprotein b, and triglycerides in adults adolescents and children aged 10 years or older or older with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate.

United Kingdom - English - myHealthbox

caduceus pharma ltd - atorvastatin - film-coated tablets - 40mg - lipid modifying agents, hmg-coa-reductase inhibitors - it is indicated as an adjunct to diet for reduction of elevated total cholesterol (total-c), ldl-cholesterol (ldl-c), apolipoprotein b, and triglycerides in adults, adolescents and children aged 10 years or older with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate.

United Kingdom - English - myHealthbox

caduceus pharma ltd - duloxetine - gastro-resistant capsule, hard - 20mg - other antidepressants - it is indicated for women for the treatment of moderate to severe stress urinary incontinence (sui).

United Kingdom - English - myHealthbox

caduceus pharma ltd - duloxetine - gastro-resistant capsule, hard - 30mg - other antidepressants - treatment of major depressive disorder. treatment of diabetic peripheral neuropathic pain. treatment of generalised anxiety disorder. duloxetine is indicated in adults.

United Kingdom - English - myHealthbox

caduceus pharma ltd - rasagiline - tablets - 1mg - anti-parkinson-drugs, monoamine oxidase -b inhibitors - it is indicated for the treatment of idiopathic parkinson’s disease (pd) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.